Based on this, it has been suggested that reducing co-morbidities in the elderly and extending the period of healthy aging will have a significant impact on decreasing the number of individuals with such impairments in 2050, with a knock-on effect of reducing the cost of dementia care.It is widely acknowledged that neuroinflammation is a critical step on the road to dementia. It is produced as a reaction to the ongoing protein deposition and cell loss observed in individuals with cognitive impairment and it has been argued that such inflammatory factors can in turn exacerbate ongoing cellular changes and hasten the progression to severe cognitive decline. This review will detail the role of the innate and adaptive immune system in the progression of AD. Specifically we will cover microglia mediated-neuroinflammation and the contribution of peripheral cells, namely T cells, on the progression to cognitive decline and the potential therapies that are under development to tackle these pathways will be discussed.
Alzheimer's DiseaseThe most common cause of cognitive impairment or dementia is AD. This accounts for 60-80% of dementia cases [5] and is characterized by the build-up of two different proteins, amyloid-β (Aβ) and tau, along with cognitive changes. Aβ is cleaved from amyloid precursor protein (APP) and these monomers aggregate into oligomers and fibrils, ultimately forming Aβ-containing plaques that are 200-650 μm 2 in size. [6] Aβ can also undergo posttranslational modifications such as phosphorylation and nitration, which accelerate this process. [7,8] Tau is a protein found in neurons that is involved in microtubule stabilization, however in AD (and other Frontotemporal dementias -FTDs) tau becomes hyperphosphorylated and accumulates forming neurofibrillary tangles (NFTs). These deposits vary considerably in size from 10 to 500 μm 2 . [9] The severity of pathological changes (particularly the NFTs) correlate with neuronal loss and the increasing cognitive decline in those with AD. [10][11][12] The observed cognitive impairment in AD differs significantly across disease stages, and ranges from mild cognitive impairment (MCI), which can progress to moderate and then severe dementia. Indeed 68-80% of those who receive an initial diagnosis of MCI go on to develop AD within 6 years. [13][14][15] MCI is the first stage of cognitive decline and features initial With the increase in the aging population, age-related conditions such as dementia and Alzheimer's disease will become ever more prevalent in society. As there is no cure for dementia and extremely limited therapeutic options, researchers are examining the mechanisms that contribute to the progression of cognitive decline in hopes of developing better therapies and even an effective, long-lasting treatment for this devastating condition. This review will provide an updated perspective on the role of immunity in triggering the changes that lead to the development of dementia. It will detail the latest findings on Aβ-and tau-induced microglial activation, i...